Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT05624996 trial: what clinicians have said so far
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- NCT05624996 ↗
- Recruiting
- NRG Oncology
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT05624996 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05624996 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8
- Interventions
- Carboplatin; Cisplatin; Computed Tomography; Durvalumab; Etoposide; Image Guided Radiation Therapy; Nab-paclitaxel; Osimertinib; Paclitaxel; Pemetrexed; Positron Emission Tomography; Questionnaire Administration; Stereotactic Body Radiation Therapy
- Arms
- Arm I (image guided RT, chemotherapy, immunotherapy) · Active comparator
- Arm II (SBRT, image guided RT, chemotherapy, immunotherapy) · Experimental
- Enrollment
- 474 (estimated)
- Primary outcomes
- Overall survival (OS)
- Progression-free survival (PFS)
- Sponsor
- NRG Oncology
- Start
- Jul 12, 2023
- Primary completion
- Oct 15, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT05624996 · updated Aug 17, 2026
Publications
linked from the registry- Heinzerling JH, Mileham KF, Robinson MM, Symanowski JT, Induru RR, Brouse GM, Corso CD, Prabhu RS, Haggstrom DE, Moeller BJ, Bobo WE, Fasola CE, Thakkar VV, Pal SE, Gregory JM, Norek SL, Begic XJ, Kesarwala AH, Burri SH, Simone CB 2nd. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025 Jan;26(1):85-97. doi: 10.1016/S1470-2045(24)00573-4. Epub 2024 Nov 29. PubMed 39615497